14. Prevalencia de gammapatías  monoclonales en una población  estadounidense de alto riesgo

Núria Claros Barrachina

Núria Claros Barrachina Hematología y Hemoterapia. Hospital General Universitario de Castellón

Palabras clave: Gammapatía monoclonal, GMSI, Espectometría de masas

Abstract

Este estudio tiene como objetivo evaluar la prevalencia y las implicaciones clínicas de las gammapatías monoclonales en una población estadounidense de alto riesgo examinada mediante espectrometría de masas. Se sugiere la asociación de esta patología con diferentes fenotipos clínicos y con una disminución de la supervivencia global.

This study aims to assess the prevalence and clinical implications of monoclonal gammopathies in a high-risk US population examined by mass spectrometry. The study suggests the association of monoclonal gammopathies with a variety of clinical phenotypes and decreased overall survival.

Recibido: 06 Abril 2023
Revisión: 11 Abril 2023
Aceptado: 05 Mayo 2023

Citas

Vol 34 N12; págs. 3111-3125. 2020. Ho M, Patel A, Goh CY, Moscvin M, Zhang L, Bianchi G.

Changing paradigms in diagnosis and treatment of monoclonal gammopathy of undetermined

significance (MGUS) and smoldering multiple myeloma (SMM). Leukemia.

Doi: https://doi.org/10.1038/s41375-020-01051-x

Vol 198 N4; págs. 641-653. 2022. Giles HV, Wechalekar A, Pratt G. The potential role of mass

spectrometry for the identification and monitoring of patients with plasma cell disorders: Where

are we now and which questions remain unanswered? . British Journal Haematology.

Doi: https://doi.org/10.1111/bjh.18226

Vol 18 N5; págs 391-396. 2018. Atkin C, Richter A, Sapey E. What is the significance of

monoclonal gammopathy of undetermined significance? . Clin Med (Lond).

Doi: https://doi.org/10.7861%2Fclinmedicine.18-5-391

Vol 116 N15; págs. 2651-2655. 2010. Kristinsson SY, Tang M, Pfeiffer RM et al. Monoclonal

gammopathy of undetermined significance and risk of skeletal fractures: a population-based

study. Blood.

Doi: https://doi.org/10.1182/blood-2010-04-282848

Vol 61 N2; págs. 140-144. 1998. Gregersen H, Madsen KM, Sørensen HT et al. The risk of

bacteremia in patients with monoclonal gammopathy of undetermined significance. European

Journal of Haematology.

Doi: https://doi.org/10.1111/j.1600-0609.1998.tb01075.x

Vol 115 N24; págs 4991-4998. 2010. Kristinsson SY, Pfeiffer RM, Björkholm M et al. Arterial

and venous thrombosis in monoclonal gammopathy of undetermined significance and multiple

myeloma: a population-based study. Blood.

Doi: https://doi.org/10.1182/blood-2009-11-252072

Vol 15 N3; págs. 177-186. 2015. Go RS, Gundrum JD, Neuner JM. Determining the clinical

significance of monoclonal gammopathy of undetermined significance: a SEER-Medicare

population analysis. Clinical Lymphoma Myeloma & Leukemia.

Doi: https://doi.org/10.1016%2Fj.clml.2014.09.004

Vol 378 N3; págs. 241-249.2018. Kyle RA, Larson DR, Therneau TM, Dispenzieri A, Kumar S,

Cerhan JR, Rajkumar SV. Long-Term Follow-up of Monoclonal Gammopathy of Undetermined

Significance. The New England Journal of Medicine.

Doi: https://doi.org/10.1056/nejmoa1709974